Skip to main content
SpringerLink
Log in

Soft tissue sarcomas & GIST Insights into subtype-specific therapy concepts: Highlights from ASCO meeting 2015

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

Sarcomas are a rare and heterogeneous group of mesenchymal malignancies that have historically been challenging in diagnosis and treatment. In soft tissue sarcomas (STS), the recognition of different histological subtypes has made a dramatic conceptual change leading to histotype-driven targeted therapies. In gastrointestinal stromal tumors (GIST), the most important advance in the past decade was the demonstration that tyrosine kinase inhibitors (TKIs) can durably control disease and lead to remarkable treatment responses. The advent of TKIs has unquestionably changed the overall survival of patients with GIST, not only in the advanced-disease setting but also in individuals with high-risk disease. This review covers the latest clinical study highlights for STS and GIST presented at American Society of Clinical Oncology (ASCO) 2015 meeting, demonstrating the constant progress from conventional chemotherapy to histology-driven therapy approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Group E.S.E.S.N.W. Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii102–12.

    Google Scholar 

  2. Eriksson M. Histology-driven chemotherapy of soft-tissue sarcoma. Ann Oncol. 2010;21 Suppl 7:vii270–6.

    PubMed  Google Scholar 

  3. Reichardt P. Soft tissue sarcomas, a look into the future: different treatments for different subtypes. Future Oncol. 2014;10(8 Suppl):s19–27.

    Article  PubMed  CAS  Google Scholar 

  4. Group E.S.E.S.N.W. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii21–6.

    Google Scholar 

  5. Blay JY, Reichardt P. Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations. Expert Rev Anticancer Ther. 2009;9(6):831–8.

    Article  PubMed  CAS  Google Scholar 

  6. Reichardt P, et al. Adjuvant therapy in primary GIST: state-of-the-art. Ann Oncol. 2012;23(11):2776–81.

    Article  PubMed  CAS  Google Scholar 

  7. Tapp WD. A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS). 2015 ASCO Annual Meeting. 2015.

  8. Mir O, et al. Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): Results of a double-blind, randomized placebo (PL) controlled phase II trial. 2015 ASCO Annual Meeting. 2015.

  9. Kim C, et al. Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma. ASCO 2015 Annual Meeting. 2015.

  10. Burgess MA. SARC 028: a phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas. 2015 ASCO Annual Meeting. 2015.

  11. Demetri GD. A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS). 2015 ASCO Annual Meeting. 2015.

  12. Seddon BM. GeDDiS: a prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas (EudraCT 2009-014907-29). 2015 ASCO Annual Meeting. 2015.

  13. Schoeffski P. Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). 2015 ASCO Annual Meeting. 2015.

  14. Joensuu H. Three vs. 1 year of adjuvant imatinib (IM) for operable high-risk GIST: The second planned analysis of the randomized SSGXVIII/AIO trial. 2015 ASCO Annual Meeting. 2015.

  15. Chandrajit PR.-. Adjuvant imatinib (IM) for patients (pts) with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence: PERSIST-5 planned 3-year interim analysis. 2015 ASCO Annual Meeting. 2015.

  16. Blay JY. Final results of the multicenter randomized phase II PAZOGIST trial evaluating the efficacy of pazopanib (P) plus best supportive care (BSC) vs BSC alone in resistant unresectable metastatic and/or locally advanced gastrointestinal stromal tumors (GIST). 2015 ASCO Annual Meeting. 2015.

  17. Chi P. A phase Ib/II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST). 2015 ASCO Annual Meeting. 2015.

Download references

Author information

Authors and Affiliations

  1. Comprehensive Cancer Center—Musculoskeletal Tumors, Medical University of Vienna, Waehringer Guertel 18–20, 1090, Vienna, Austria

    Sophie Schur MD &  Thomas Brodowicz MD

  2. Department of Internal Medicine I/Oncology, Medical University of Vienna, Waehringer Guertel 18–20, 1090, Vienna, Austria

    Sophie Schur MD &  Thomas Brodowicz MD

  3. Sarcoma Platform Austria, Vienna, Austria

    Sophie Schur MD &  Thomas Brodowicz MD

Authors
  1. Sophie Schur MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Brodowicz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Brodowicz MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schur, S., Brodowicz, T. Soft tissue sarcomas & GIST Insights into subtype-specific therapy concepts: Highlights from ASCO meeting 2015. memo 8, 205–208 (2015). https://doi.org/10.1007/s12254-015-0233-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-015-0233-5

Keywords

Search

Navigation